Inhibition of PCSK9 transcription by Berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway

Journal of Biological Chemistry

Volumn 290, Issue 7, 2015, Pages 4047-4058

  Dong, Bin ^a   Li, Hai ^a   Singh, Amar Bahadur ^a   Cao, Aiqin ^a   Liu, Jingwen ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION;

DEGRADATION PATHWAYS; DOWN-REGULATION; PROTEASOMAL DEGRADATION; PROTEASOMES; PROTEIN EXPRESSIONS; PROTEIN STABILITY; UBIQUITIN;

PROTEINS;

BAFILOMYCIN A1; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BERBERINE; BORTEZOMIB; GREEN FLUORESCENT PROTEIN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HYBRID PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROTEASOME; UBIQUITIN; PCSK9 PROTEIN, MOUSE; SERINE PROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CELLULAR DISTRIBUTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEGRADATION KINETICS; DOWN REGULATION; DRUG MECHANISM; DYSLIPIDEMIA; GENE; GENE EXPRESSION REGULATION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; LIVER CELL; LYSOSOME; MALE; MOUSE; NONHUMAN; PCSK9 GENE; PHARMACOLOGICAL BLOCKING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; HAMSTER; HEK293 CELL LINE; LIVER; MESOCRICETUS; METABOLISM; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BERBERINE; BLOTTING, WESTERN; CELLS, CULTURED; CRICETINAE; GENE EXPRESSION REGULATION; HEK293 CELLS; HEP G2 CELLS; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; LIVER; MALE; MESOCRICETUS; MICE; PROMOTER REGIONS, GENETIC; PROPROTEIN CONVERTASES; PROTEASOME ENDOPEPTIDASE COMPLEX; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE ENDOPEPTIDASES; TRANSCRIPTION, GENETIC; UBIQUITIN;

EID: 84922831823     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.597229     Document Type: Article

References (42)

1. Peterson, A. S., Fong, L. G., and Young, S. G. (2008) PCSK9 function and physiology. J. Lipid Res. 49, 1595-1599
2. Qian, Y.-W., Schmidt, R. J., Zhang, Y., Chu, S., Lin, A., Wang, H., Wang, X., Beyer, T. P., Bensch, W. R., Bensch, W. R., Li, W., Ehsani, M. E., Lu, D., Konrad, R. J., Eacho, P. I., Moller, D. E., Karathanasis, S. K., and Cao, G. (2007) Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J. Lipid Res. 48, 1488-1498
3. Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., and Chretien, M. (2003) The secretory proprotein convertase neutal apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U.S.A. 100, 928-933
4. Seidah, N. G. (2009) PCSK9 as a therapeutic target of dyslipidemia. Expert Opin. Ther. Targets 13, 19-28
5. Zhang, D. W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2007) Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeatAof low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282, 18602-18612
6. McNutt, M. C., Kwon, H. J., Chen, C., Chen, J. R., Horton, J. D., and Lagace, T. A. (2009) Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J. Biol. Chem. 284, 10561-10570
7. Lambert, G., Ancellin, N., Charlton, F., Comas, D., Pilot, J., Keech, A., Patel, S., Sullivan, D. R., Cohn, J. S., Cohn J. S., Rye, K. A., Barter, P. J. (2008) Plasma PCSK9 concentration correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin. Chem. 54, 1038-1045
8. Grefhorst, A., McNutt, M. C., Lagace, T. A., and Horton, J. D. (2008) Plasma PCSK9 preferentially reduces liver LDL receptors in Mice. J. Lipid Res. 49, 1303-1311
9. Ling, H., Burns, T. L., and Hilleman, D. E. (2014) An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol. Cardiovasc. Ther. 32, 82-88
10. Horton, J. D., Shah, N. A., Warrington, J. A., Anderson, N. N., Park, S. W., Brown, M. S., and Goldstein, J. L. (2003) Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. U.S.A. 100, 12027-12032
11. Dubuc, G., Chamberland, A., Wassef, H., Davignon, J., Seidah, N. G., Bernier, L., and Prat, A. (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24, 1454-1459
12. Jeong, H. J., Lee, H.-S., Kim, K.-S., Kim, Y.-K., Yoon, D., and Park, S. W. (2008) Sterol-dependent regulation of proprotein convertase subtilisin/ kexin type 9 expression by sterol-regulatroy element binding protein-2. J. Lipid Res. 49, 399-409
13. Mendel, D. B., and Crabtree, G. R. (1991) HNF-1, a member of a novel class of dimerizing homeodomain proteins. J. Biol. Chem. 266, 677-680
14. Li, H., Dong, B., Park, S. W., Lee, H. S., Chen, W., and Liu, J. (2009) Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J. Biol. Chem. 284, 28885-28895
15. Dong, B., Wu, M., Li, H., Kraemer, F. B., Adeli, K., Seidah, N. G., Park, S. W., and Liu, J. (2010) Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J. Lipid Res. 51, 1486-1495
16. Li, H., and Liu, J. (2012) The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells. Biochem. J. 443, 757-768
17. Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., Wang, S., Wu, J., Wang, Y., Li, Z., Liu, J., and Jiang, J. D. (2004) Berberine is a promising novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 10, 1344-1351
18. Cameron, J., Ranheim, T., Kulseth, M. A., Leren, T. P., and Berge, K. E. (2008) Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 201, 266-273
19. Cao, A., Wu, M., Li, H., and Liu, J. (2011) Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells. J. Lipid Res. 52, 518-530
20. Singh, A. B., Kan, C. F., Shende, V., Dong, B., Liu, J. (2014) A novel posttranscriptional mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression. J. Lipid Res. 55, 1397-1407
21. Thompson, J. L. (2013) Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Ann. Pharmacother. 47, 56-62
22. Wu, M., Dong, B., Cao, A., Li, H., and Liu, J. (2012) Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters. Atherosclerosis 224, 401-410
23. Astudillo, A. M., Pérez-Chacon, G., Meana, C., Balgoma, D., Pol, A., Del Pozo, M. A., Balboa, M. A., and Balsinde, J. (2011) Altered arachidonate distribution in macrophages from caveolin-1 null mice leading to reduced eicosanoid synthesis. J. Biol. Chem. 286, 35299-35307
24. Dong, B., Kan, C. F., Singh, A. B., and Liu, J. (2013) High-fructose diet downregulates long-chain acyl-CoA synthetase 3 expression in liver of hamsters via impairing LXR/RXR signaling pathway. J. Lipid Res. 54, 1241-1254
25. Dong, B., Singh, A. B., Fung, C., Kan, K., and Liu, J. (2014) CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis 235, 449-462
26. Matsui, C., Shoji, I., Kaneda, S., Sianipar, I. R., Deng, L., and Hotta, H. (2012) Hepatitis C virus infection suppresses GLUT2 gene expression via downregulation of hepatocyte nuclear factor 1α. J. Virol. 86, 12903-12911
27. Hershko, A. (2005) The ubiquitin system for protein degradation and some of its roles in the control of the cell-division cycle (Nobel lecture). Angew. Chem. Int. Ed. Engl. 44, 5932-5943
28. Hershko, A., Ciechanover, A., and Varshavsky, A. (2000) Basic Medical Research Award. The ubiquitin system. Nat. Med. 6, 1073-1081
29. Huang, L., and Chen, C. H. (2009) Proteasome regulators: activators and inhibitors. Curr. Med. Chem. 16, 931-939
30. Careskey, H. E., Davis, R. A., Alborn, W. E., Troutt, J. S., Cao, G., and Konrad, R. J. (2008) Atovastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res. 49, 394-398
31. Raal, F., Panz, V., Immelman, A., and Pilcher, G. (2013) Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J. Am. Heart Assoc. 2, e000028
32. Costet, P., Hoffmann, M. M., Cariou, B., Guyomarc'h Delasalle, B., Konrad, T., and Winkler, K. (2010) Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 212, 246-251
33. Welder, G., Zineh, I., Pacanowski, M. A., Troutt, J. S., Cao, G., and Konrad, R. J. (2010) High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J. Lipid Res. 51, 2714-2721
34. Cereghini, S. (1996) Liver-enriched transcription factors and hepatocyte differentiation. FASEB J. 10, 267-282
35. Shih, D. Q., Bussen, M., Sehayek, E., Ananthanarayanan, M., Shneider, B. L., Suchy, F. J., Shefer, S., Bollileni, J. S., Gonzalez, F. J., Breslow, J. L., and Stoffel, M. (2001) Hepatocyte nuclear factor-1α is an essential regulator of bile acid and plasma cholesterol metabolism. Nat. Genet. 27, 375-382
36. Pontoglio, M., Barra, J., Hadchouel, M., Doyen, A., Kress, C., Bach, J. P., Babinet, C., and Yaniv, M. (1996) Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 84, 575-585
37. Shih, D. Q., Screenan, S., Munoz, K. N., Philipson, L., Pontoglio, M., Yaniv, M., Polonsky, K. S., and Stoffel, M. (2001) Loss of HNF-1α function in mice leads to abnormal expression of genes involved in pancreatic islet development and metabolism. Diabetes 50, 2472-2480
38. Costa, R. H., Kalinichenko, V. V., Holterman, A. X., and Wang, X. (2003) Transcription factors in liver development, differentiation, and regeneration. Hepatology 38, 1331-1347
39. Armendariz, A. D., and Krauss, R. M. (2009) Hepatic nuclear factor 1-α: inflammation, genetics, and atherosclerosis. Curr. Opin. Lipidol. 20, 106-111
40. Pontoglio, M., Pausa, M., Doyen, A., Viollet, B., Yaniv, M., and Tedesco, F. (2001) Hepatocyte nuclear factor 1α controls the expression of terminal complement genes. J. Exp. Med. 194, 1683-1689
41. Park, I. N., Cho, I. J., and Kim, S. G. (2004) Ceramide negatively regulates glutathione S-transferase gene transactivation via repression of hepatic nuclear factor-1 that is degraded by the ubiquitin proteasome system. Mol. Pharmacol. 65, 1475-1484
42. Yoshizawa, K., Mukai, H. Y., Miyazawa, M., Miyao, M., Ogawa, Y., Ohyashiki, K., Katoh, T., Kusumoto, M., Gemma, A., Sakai, F., Sugiyama, Y., Hatake, K., Fukuda, Y., and Kudoh, S. (2014) Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization. Cancer Sci. 105, 195-201